Efficacy, safety profile, and immunogenicity of alglucosidase alfa produced at the 4,000-liter scale in US children and adolescents with Pompe disease: ADVANCE, a phase IV, open-label, prospective study

on behalf of the Pompe ADVANCE Study Consortium

Research output: Contribution to journalArticlepeer-review

9 Scopus citations

Fingerprint

Dive into the research topics of 'Efficacy, safety profile, and immunogenicity of alglucosidase alfa produced at the 4,000-liter scale in US children and adolescents with Pompe disease: ADVANCE, a phase IV, open-label, prospective study'. Together they form a unique fingerprint.

Biochemistry, Genetics and Molecular Biology

Medicine and Dentistry

Psychology

Pharmacology, Toxicology and Pharmaceutical Science

Neuroscience